A Phase 1 interventional study of Metformin and Metformin in Generalized Anxiety Disorder, sponsored by Pfizer. Terminated at 1 site in Singapore. Open to participants aged 21 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2010-02-17.
Sponsored by Pfizer · Phase 1 and Interventional
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies testing imagabalin in Generalized Anxiety Disorder — none open to participants now, none under way, none of them phase 3. imagabalin · Generalized Anxiety Disorder.
Among the 11 studies testing imagabalin in Generalized Anxiety Disorder, this one is the 7th largest by enrollment, is one of 4 that started in 2009, is one of 4 in phase 1, and was the 9th registered.
518 studies on the registry are indexed under Generalized Anxiety Disorder; 125 are open to participants now.
Browse Generalized Anxiety Disorder studies →None of the 11 studies testing imagabalin in Generalized Anxiety Disorder is open now. The open studies under Generalized Anxiety Disorder, anywhere →
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 87 Generalized Anxiety Disorder studies recruiting now, 32 (37%) set no upper age limit and 53 (61%) stop at 75 or younger; 15 take children under 18; 16 take healthy volunteers.
This study: 21 Years to 55 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
First in 2005; this study’s year is marked. 4 started in 2009.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 24 is below the median of 83 across 440 interventional studies indexed under Generalized Anxiety Disorder.
Median enrollment 222 across the 11 interventional studies. Of the 9 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
11 of 11 have an industry lead sponsor. The 1 most frequent:
Pfizer is the lead sponsor of 3,337 studies on the registry; 146 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
14 studies in Generalized Anxiety Disorder by Pfizer: none open now, none under way, none of them phase 3. Of 12 finished, 1 (8%) have results posted.
Among the 14 studies in Generalized Anxiety Disorder by Pfizer, this one is the 9th largest by enrollment of the 13 interventional ones that give a count, is one of 4 that started in 2009, is one of 4 in phase 1, and was the 10th registered.
Pfizer’s Generalized Anxiety Disorder studies by the year they started, since 2003.
None of the studies under way reaches primary completion within a year.
Among the 11 studies testing imagabalin in Generalized Anxiety Disorder, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Pfizer’s 14 in Generalized Anxiety Disorder:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Detailed Description:
Additional Study Purpose Details: To assess the pharmacokinetics of metformin and PD 0332334 with concurrent administration.
On February 18th 2009, a decision to terminate further development for PD 0332334 was communicated to investigators in this study. The decision to terminate this study was not based on any safety concerns.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
This is an open-label, randomized, two period cross-over which will be conducted in 12 healthy adults
Drug: Metformin
This is an open-label, randomized, two period cross-over which will be conducted in 12 healthy adults
Drug: PD 0332334
225 mg q12, oral PD 0332334 immediate release formulation on Days 1 through 5; Single, oral, 500 mg dose of metformin immediate release
Also known as: imagabalin
Single, oral, 500 mg of metformin immediate release
500 mg q12, oral metformin immediate release administered on Days 1 through Day 6 Single, oral, 300 mg dose of PD 0332334 immediate release formulation administered on Day 3
Single, oral, 300 mg dose of PD 0332334 immediate release formulation
Metformin and PD 0332334 area under the curve (AUC) from time 0 to infinity (AUCinf)
Time frame: Days 1 through 7
Metformin and PD 0332334 AUC from 0 to last quantifiable concentration (AUClast)
Time frame: Days 1 through 7
Metformin and PD 0332334 half-life (t1/2)
Time frame: Days 1 through 7
Metformin and PD 0332334 maximum plasma concentration
Time frame: Days 1 through 7
Clinical safety laboratories
Time frame: Days 1 through 7
Incidence, duration and severity of adverse events when study medications administered alone and concurrently
Time frame: Days 1 through 7
Discontinuation due to adverse events when study medications administered alone and concurrently
Time frame: Days 1 through 7
12-lead ECGs
Time frame: Days 1 through 7
Vital signs
Time frame: Days 1 through 7
The record gives a start of Jan 2009, a primary completion of Feb 2009 and a completion of Feb 2009. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Feb 2010. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Metformin · Imagabalin
Generalized Anxiety Disorder →